Predicting Hepatic Steatosis in Living Liver Donors via Noninvasive Methods

Abstract

Hepatic steatosis assessment is of paramount importance for living liver donor selection because significant hepatic steatosis can affect the postoperative outcome of recipients and the safety of the donor. The validity of various noninvasive imaging methods to assess hepatic steatosis remains controversial. The purpose of our study is to investigate the association between noninvasive imaging methods and pathology to detect steatosis in living liver donors and to propose a prediction model for hepatic steatosis.Liver stiffness measurements (LSMs) and controlled attenuation parameter values in vibration controlled transient elastography, ultrasonography, computed tomography (CT), and magnetic resonance imaging were used as pretransplant screening methods to evaluate living liver donors between 2012 and 2014. Only 1 pathologist assessed tissue sample for hepatic steatosis.The median age of the 79 living donors (53 men and 26 women) was 32 years (16–68 years). The CT liver–spleen attenuation (L–S) difference and the controlled attenuation parameter values were well correlated with the level of hepatic steatosis on liver pathology. Multivariate analysis showed that liver stiffness measurement (LSM) (β 0.903; 95% CI, 0.105–1.702; P = 0.027) and the CT L to S attenuation difference (β = −3.322; 95% CI, −0.502 to −0.142; P = 0.001) were closely associated with hepatic steatosis. We generated the following equation to predict total hepatic steatosis: Hepatic steatosis = 0.903 × LSM – 0.322 × CT L to S attenuation difference (AUC = 86.6% and P = 0.001). The values predicted by the equation correlated well with the presence of hepatic steatosis (r = 0.509 and P < 0.001).The combination of nonenhanced CT L to S attenuation difference and transient elastography using vibration controlled transient elastography provides sufficient information to predict hepatic steatosis in living liver donor candidates.

Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study

“…Third, NAFLD was measured by ultrasound after exclusion of secondary causes for fatty liver. Although the accuracy of ultrasound for establishing the presence of fatty liver is high, it is subject to measurement error 6 , 39 . Similarly, we used eGFR as an outcome, which has inherent limitations derived from using creatinine as a filtration marker.…”

“…Nonalcoholic fatty liver disease (NAFLD), characterized by excessive hepatic fat accumulation without significant alcohol intake, use of medications causing fatty liver, or other traditional causes of fatty liver, is the most common cause of chronic liver disease worldwide, especially in developed countries 5 , 6 . The global prevalence of NAFLD was estimated at 25.2% 7 .…”

PNPLA3gene predicts clinical recovery after sustained virological response in decompensated hepatitis C cirrhosis

“…We were unable to support that the effect of PNPLA3 is mechanistically related to hepatic steatosis. We measured hepatic steatosis using CT L−S , a method widely validated in the field of living-donor liver transplantation18 and in the general population,19 and found that it did not correlate with the primary outcome nor with any other genetic ( PNPLA3, TM6SF2, MBOAT7 ) or phenotypic (BMI, diabetes) parameters. We speculate that in the setting of advanced cirrhosis, liver density is overwhelmingly increased relative to hepatic steatosis.…”

Perioperative glucose management and outcomes in liver transplant recipients: A qualitative systematic review

“…As NAFLD increases prevalence, the transplant community will see more NAFLD among both living donors as well. A reliable assessment of hepatic steatosis is of paramount importance for living donor selection as significant steatosis can impact the postoperative outcomes of recipients and safety of the donor[ 33 ]. Because of these challenges, the focus could be on developing and establishing a standardized protocol for the monitoring of blood glucose levels.…”